Inotiv, Inc.

As of February 10, 2022, Inotiv, Inc. is considered risky and overvalued with poor financial metrics and significant underperformance, reflected in a year-to-date return of -64.98% and a 3-year return of -93.17%, compared to the S&P 500's gains.

As of February 10, 2022, Inotiv, Inc. is considered overvalued and risky due to poor financial metrics, including a negative ROCE and ROE, a high EV to EBITDA ratio compared to peers, and significant underperformance relative to the S&P 500.

As of June 11, 2025, Inotiv, Inc. is in a mildly bearish trend, influenced by bearish daily moving averages and Bollinger Bands, despite some mildly bullish signals on the weekly MACD and KST.

As of March 2022, the management team of Inotiv, Inc. includes Dr. Gregory Davis (Interim Chairman), Mr. Robert Leasure (President and CEO), Dr. John Sagartz (Chief Strategy Officer), and three Independent Directors: Dr. Richard Johnson, Mr. R. Matthew Neff, and Ms. Wendy Perrow. They oversee the company's strategic direction and operations.

Inotiv, Inc. is an international contract research company specializing in drug discovery and development services, with a market capitalization of $70.42 million. As of March 2025, it reported net sales of $124 million and a net loss of $15 million.

As of Jun 18, Inotiv, Inc. has a market capitalization of 70.42 million, with net sales of 480.41 million and a net profit of -87.48 million over the latest four quarters. The company reported shareholder's funds of 170.50 million and total assets of 841.43 million as of Sep 24.